(NASDAQ: ACXP) Acurx Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.62%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.53%.
Acurx Pharmaceuticals's earnings in 2026 is -$7,966,538.On average, 5 Wall Street analysts forecast ACXP's earnings for 2026 to be -$6,280,484, with the lowest ACXP earnings forecast at -$7,498,438, and the highest ACXP earnings forecast at -$5,066,242. On average, 5 Wall Street analysts forecast ACXP's earnings for 2027 to be -$6,086,342, with the lowest ACXP earnings forecast at -$7,134,707, and the highest ACXP earnings forecast at -$5,545,886.
In 2028, ACXP is forecast to generate -$6,042,660 in earnings, with the lowest earnings forecast at -$6,854,915 and the highest earnings forecast at -$5,096,220.